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Background: Studies have shown that pharmaceutical care can result in favorable clinical outcomes in human
immunodeficiency virus (HIV)-infected patients, however, few studies have assessed the economic impact. The
objective of this study was to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected
patients.
Methods: A controlled ambispective study was conducted in Brazil from January 2009 to June 2012. Patients
were allocated to either intervention or control group. The control group was followed according to standard
care while the intervention group was also followed by a pharmacist at each physician appointment for one year.
Effectiveness outcomes included CD4+ count, viral load, absence of co-infections and optimal immune response,
and economic outcomes included expenses of physician and pharmaceutical appointments, laboratory tests,
procedures, and hospitalizations, at six months and one year.
Results: Intervention and control groups included 51 patients each. We observed significant decreases in total
pharmacotherapy problems during the study. At six months, the intervention group contained higher percentages
of patients without co-infections and of patients with CD4+ >500 cells/mm3. None of the differences between
intervention and control group considering clinical outcomes and costs were statistically significant. However, at
one year, the intervention group showed higher percentage of better clinical outcomes and generated lower
spending (not to procedures). An additional health care system daily investment of US$1.45, 1.09, 2.13, 4.35, 1.09,
and 0.87 would be required for each additional outcome of viral load <50 copies/ml, absence of co-infection,
CD4+ >200, 350, and 500 cells/mm3, and optimal immune response, respectively.
Conclusion: This work demonstrated that pharmaceutical care of HIV-infected patients, for a one-year period,
was able to decrease the number of pharmacotherapy problems. However, the clinical outcomes and the costs
did not have statistical difference but showed higher percentage of better clinical outcomes and lower costs for
some items.
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Since 1996, Brazil has had a public health system pro-
gram that provides free antiretroviral therapy, laboratory
tests, and procedures to HIV-infected patients. This
program has been internationally recognized as a major
initiative against HIV [1]. However, this program alone
does not guarantee safety and effectiveness of treatment
because HIV treatment requires long-term therapy.
Treatment of HIV includes a large number of drugs and
drug interactions, and requires careful monitoring of
therapy, with the goal of decreasing viral resistance and
drug-related problems [1-3].
Studies have investigated the effects of pharmaceutical
care on the rational use of drugs in HIV-infected
patients [4-6]. March et al. demonstrated that HIV-
infected patients followed by a clinical pharmacist
show significant improvements in CD4+ levels and
viral load and a decrease in toxic effects related to
treatment [7]. This reduction in toxicity improves the
quality of life and treatment adherence of the patients
[8]. In addition, a systematic analysis (including data
from January 1980 to June 2011) revealed that provid-
ing pharmaceutical care to HIV-infected patients was
associated with statistically significant improvements
in treatment adherence and had a positive impact on
viral suppression [9].
Despite the variety of pharmaceutical care studies
conducted with HIV-infected patients, remarkably few
include an economic analysis. There is a need to go be-
yond the investigation of clinical outcomes generated by
pharmaceutical care. Studies that include the economic
impact of pharmaceutical care are necessary to justify
the implementation or expansion of pharmaceutical care
services [10].
In addition to the lack of economic studies on
pharmaceutical care conducted with HIV-infected pa-
tients, another limitation is that, even though the
studies available demonstrate that pharmaceutical care
practice can contribute to the reductions of costs, they
focus only on the costs associated with drugs, physician
appointments, and hospitalizations. The available litera-
ture does not present studies regarding the impact of
pharmaceutical care on the costs associated with la-
boratory tests and procedures [9,11-13]. Moreover, the
majority of pharmacoeconomic studies present many
methodological limitations, such as the lack of a control
group and non-inclusion of costs associated with
pharmacist appointments [14]. Thus, it has become im-
perative to conduct well-designed studies in the area of
pharmaceutical care in order to obtain a clearer compre-
hension of its economic impact [14]. Well-designed stud-
ies investigating economic impact should be encouraged
because they enable the rationalization of resources in
health care, where the available resources are limited [15].This study was designed to perform a pharmacoeco-
nomic analysis of the impact of pharmaceutical care
on HIV-infected patients over a one-year period by
measuring both clinical and health care system eco-
nomic outcomes.
Methods
This was a one-year, ambispective, controlled study, with
a systematic sample by quota controls, paired according
to random characteristics. A retrospective chart review
and a prospective pharmaceutical care follow-up were
conducted. The study was conducted at a hospital in the
state of São Paulo, Brazil. The Hospital Ethics Committee
approved the research, and informed consent was ob-
tained from all patients.
The inclusion criteria for the study were as follows: out-
patients diagnosed with HIV/AIDS (Human Immunodefi-
ciency Virus/Acquired Immunodeficiency Syndrome), aged
between 18 and 60 years, having body mass index (BMI)
lower than 30 kg/m2, and receiving antiretroviral therapy
(ART). Obese patients were not included because they
present higher incidences of hyperlipidemia, hypertension,
and insulin resistance, and because some HIV/AIDS medi-
cations such as protease inhibitors can cause weight gain
and fat accumulation, it would not be possible to determine
whether the weight gain was related to the medication or
to the background disease in such patients [16-19]. Patients
who were unable to return for later appointments/exams,
who refused to participate, who have psychiatric disease
(that unable them to follow the medical appointments
schedule and the pharmacist interventions), and those who
were pregnant were excluded. Patients were enrolled in
the study from January 2009 to June 2011 and were
assigned in a 1:1 ratio to either intervention or control
group by the clinical pharmacy team. Control group
patients were matched to intervention group patients
according to gender and baseline CD4+ count.
For one year, the intervention group was followed by
the clinical pharmacy staff, composed of two pharma-
cists trained by the hospital clinical pharmacy team
regarding HIV/AIDS and pharmaceutical care, after rou-
tine medical appointments at the hospital, using a
method developed and adapted to the reality of the hos-
pital, based on the Pharmacist’s Workup of Drug Ther-
apy (PWDT) method [20]. The control group was not
followed by the clinical pharmacy team, and its data
were collected through review of medical charts encom-
passing the same period.
Initial and final pharmacotherapy problems were
accounted for and classified as necessity, effectiveness,
safety, or therapy compliance pharmacotherapy prob-
lems only for the intervention group [21]. The clinical
pharmacy team performed written and verbal pharma-
cist interventions with the intervention group, which
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or pharmacist-physician interventions and as resolutive
pharmacotherapy problems, preventive pharmacotherapy
problems, quality of life, or referral to other medical spe-
cialties interventions. The classifications used for pharma-
cotherapy problems and pharmacist interventions are in
accordance with those used in another publication by the
authors [22].
The five effectiveness outcomes were as follows: CD4+
count higher than 200 cells/mm3, 350 cells/mm3, and
500 cells/mm3; viral load lower than 50 copies/ml; and
absence of co-infections. The co-infections considered
by the study were as follows: bacterial co-infections
(urinary infection, shigellosis, infected sebaceous cysts, cel-
lulitis, pneumonia, and hordeolums), viral co-infections
(cytomegalovirus, influenza, Herpes zoster, Herpes simplex,
human papillomavirus, viral conjunctivitis, and warts),
parasitic co-infection (microsporidiosis, isosporiasis, coc-
cidiosis, and neurocryptococcosis), and fungal co-infections
(oral moniliasis, onychomycosis, and tinea pedis). Effective-
ness outcomes were measured at six months and one year
of study and were obtained through medical chart review
for both groups. Additionally, using a decision tree model,
we established the number of patients from both groups
that achieved, after one year of study, an optimal immune
response as characterized by viral load <50 copies/ml, ab-
sence of co-infection, and CD4+>500 cells/mm3.
For cost analysis, we identified the number of appoint-
ments (medical/nursing/nutrition/physical therapy/speech
therapy/dental), laboratory tests, procedures, and hospital-
izations per patient in the first six months, the last six
months, and in one year, for both groups, through review
of their medical charts. For the intervention group, we also
included the cost of the pharmacist appointment. The
DATASUS database [23] provided the monetary values for
all these items. Values were quoted in US dollars ($).Figure 1 Flow diagram of the patients included in the study.Cost analysis was performed for the one-year period,
considering both the effectiveness and the costs of ap-
pointments, laboratory tests, procedures, hospitaliza-
tions, total cost, and total cost without procedures.
Statistical analysis of the results was performed by
SAS System for Windows (Statistical Analysis System,
version 9.2). For baseline characteristics analysis, chi-
square, Fisher’s exact, and Mann–Whitney tests were
performed. For co-infection, CD4+ and viral load ana-
lysis and generalized estimating tests were performed.
For costs analysis, ANOVA for repeated measures, with
a transformation by positions, was performed. The sig-
nificance level was set at 5% (P ≤0.050).
Results
The study screened 140 HIV-infected patients being
treated at the hospital on an outpatient basis. Thirty-
eight patients were excluded: two were pregnant; nine
interrupted the treatment at the hospital; eight were
transferred from the hospital; and nineteen had not
returned for the second pharmaceutical appointment in
the first six months of the study (Figure 1). Finally, 51
patients each were allocated to intervention and control
groups. A medical chart review provided the demo-
graphic data and initial information for both study
groups (Table 1). The two study groups had similar
baseline characteristics, indicating homogeneity.
There were a total of 230 pharmaceutical appoint-
ments (143 in the initial six months and 87 in the final
six months). During these appointments, 219 pharmacist
interventions were performed. Among them, 185 (84.5%)
were pharmacist-patient interventions and 34 (15.5%)
were pharmacist-physician interventions; 116 (53.0%) were
preventive interventions, 55 (25.1%) were resolutive inter-
ventions, 42 (19.2%) were quality of life interventions, and
six (2.7%) were referral to other medical specialties









Age (Mean [SD], years) 40.5 [9.2] 41.3 [8.8] 0.580a
Men - % (n) 66.7 (34) 66.7 (34) 1.000b
Ethnicity - % (n) 0.830b
Caucasian 70.6 (36) 68.6 (35)
Black/ african descent 29.4 (15) 31.4 (16)
HIV Diagnosis(Mean [SD], years) 7.5 [5.6] 8.3 [6.4] 0.690a
HIV Treatment Duration (Mean
[SD], years)
5.7 [4.2] 6.5 [5.5] 0.780a
Number of tablets/day (Mean [SD]) 9.3 [4.4] 10.1 [4.2] 0.250a
ART changes during the first 4
weeks of the study - % (n)
9.8 (5) 7.8 (4) 1.000c
CD4 + (Mean [SD], cells/mm3) 304.0
[277.1]
310.4 [302.0] 0.980a
CD4 + >200 cells/mm3 % (n) 56.9 (29) 54.9 (28) 0.840b
CD4 + >350 cells/mm3 % (n) 31.4 (16) 33.3 (17) 0.830b
CD4 + >500 cells/mm3 % (n) 15.7 (8) 17.7 (9) 0.800b
Viral load <50 copies/ml % (n) 60.8 (31) 64.8 (33) 0.190b
Number of Comorbidities
(Mean [SD])
2.5 [1.6] 2.8 [2.1] 0.730a
Type of comorbidities % (n)
Hepatitis C 23.5 (12) 21.6 (11) 0.630b
Tobaccoism 15.8 (8) 11.8 (6) 0.570b
Neurotoxoplasmosis 9.8 (5) 9.8 (5) 0.510b
Hypertriglyceridemia 3.9 (2) 9.8 (5) 0.440c
Pulmonary tuberculosis 13.7 (7) 3.9 (2) 0.160c
ART regimen % (n) 0.800b
TDF+3TC+EFV 17.6 (9) 21.6 (11)
AZT+3TC+EFV 15.7 (8) 21.6 (11)
AZT+3TC+LPV/r 9.8 (5) 7.8 (4)
TDF+3TC+LPV/r 11.8 (6) 11.8 (6)
Others 45.1 (23) 37.2 (19)
Substance abuse % (n) 0.418b
Alcohol 19.6 (10) 29.4 (15)
Tobacco 27.4 (14) 33.3 (17)
Illicit drugs 13.73 (7) 7.8 (4)
Note: aMann-Whitney test; bChi-square test;cFisher’s exact test.
Abbreviations: ART, antiretroviral therapy; AZT, zidovudine; CD4+, lymphocyte T
CD4+; EFV, efavirenz; LPV/r, lopinavir/ritonavir; n, absolute number of patients;
SD, standard deviation; TDF, tenofovir; 3TC, lamivudine.
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in total pharmacotherapy problems (from 248 to 145;
41.5%, P <0.001), necessity problems (from 55 to 26; 52.7%,
P <0.001), and safety problems (from 161 to 96; 40.4%,
P <0.001). A decrease in the other pharmacotherapy prob-
lems was also detected; however, it was not statisticallysignificant: effectiveness problems (from 12 to 11;
8.4%, P =1.0000) and compliance problems (from 20
to 12; 40.0%, P =0.760).
Regarding clinical outcomes, in the initial six months,
the intervention group contained higher percentages
of patients without co-infections and of patients with
CD4+ >500 cells/mm3. At one year, the intervention
group showed higher percentage of better clinical out-
comes: absence of co-infection, viral load <50 copies/
ml, CD4+ >200 cells/mm3, CD4+ >350 cells/mm3, and
CD4+ >500 cells/mm3 (Table 2). However, none of these
differences was statistically significant. In addition, by
using the decision tree model to establish the number of
patients from each study group that achieved an optimal
immune response (Figure 2), it was possible to infer
that pharmaceutical care improves a patient’s immune
response.
At six months, the intervention group presented with
two bacterial, five viral, and two fungal co-infections
and, at one year, presented with two bacterial, one viral,
two parasitic, and one fungal co-infections. At six
months, the control group presented with five bacterial,
three viral, two parasitic, and one fungal co-infections,
and at one year, presented with one bacterial, five viral,
and three parasitic co-infections.
At one year of study, the intervention group spent less
per day on appointments, laboratory tests, and hospitaliza-
tions, but spent more on procedures and in total than the
control group. Moreover, only the intervention group
spent on pharmaceutical appointments. Compared with
the control group, the intervention group annually gener-
ated savings per patient of $3.20 associated with appoint-
ments, $23.19 with laboratory tests, and $5.94 with
hospitalizations. The intervention group also generated
additional annual costs per patient of $50.60 associated
with procedures, $12.88 with pharmaceutical appoint-
ments, and $31.13 with total costs (Table 3). However,
the difference in costs between the groups was not sta-
tistically significant. The stark contrast in the costs as-
sociated with procedures was caused by two hip
surgeries performed on patients from the intervention
group, which together added $1,916.09 to the total ex-
penses. This amount corresponds to 48.0% of the total
spent on procedures in the first six months of the study
($3,991.04). Excluding the costs of these procedures from
the total costs, the results demonstrate that compared
with the control group, the intervention group would have
spent $19.40 less per patient per year (Table 3).
Cost analysis identified the additional costs associated
with procedures and total costs required to achieve each
of the clinical outcomes outlined in the study (Table 4).
Moreover, we found that, for each $1.00 spent on pharma-
ceutical care, there was a loss of $1.42 per day. However,
when the costs associated with procedures were excluded
Table 2 Co-infection, viral load and CD4+ at baseline, 6 months, and at one year of study
Control Group Intervention Group P valuea
N=51 N=51
Basal 6 months 1 year Basal 6 months 1 year
% (n) % (n) % (n) % (n) % (n) % (n)
Absence of co-infection / 72.6 (37) 56.9 (29) / 76.5 (39) 64.7 (33) 0.092
Viral load <50 copies/ml 60.8 (31) 76.5 (39) 68.6 (35) 64.8 (33) 58.8 (30) 74.5 (38) 0.869
CD4+>200 cells/mm3 56.9 (29) 68.6 (35) 74.5 (38) 54.9 (28) 70.8 (34) 78.4 (40) 0.793
CD4+>350 cells/mm3 31.4 (16) 37.3 (19) 49.0 (25) 33.3 (17) 37.5 (18) 51.0 (26) 0.977
CD4+>500 cells/mm3 15.7 (8) 17.7 (9) 19.6 (10) 17.7 (9) 20.8 (10) 27.5 (14) 0.599
Note: aStatistical significance value - Generalized estimating equations (GEE) test.
Abbreviation: CD4+, lymphocyte T CD4+.
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care, there was a benefit of $2.51 per day. No relationship
could be identified between the total daily costs generated
by the patients and the reductions of pharmacotherapy
problems (P =0.292; correlation R =0.15039; Spearman
correlation coefficient test), or between the total costs and
the number of pharmacist interventions (P =0.706; correl-
ation R = −0.05412; Spearman correlation coefficient test).
Discussion
Pharmaceutical interventions were mostly of the pharmacist-
patient type, which prevented therapy compliance errors
(i.e., the patients needed clarifications regarding the
use of medication, especially regarding dosage, drug
interactions, and adherence). This type of intervention
can help increase patient adherence to therapy. Hirsch
et al. demonstrated in a cohort study with 2,234 pa-
tients that patients undergoing pharmaceutical care
had greater adherence to antiretroviral therapy than
patients not undergoing pharmaceutical care [6].
The decreases observed for all pharmacotherapy prob-
lem types are consistent with the literature. Studies have
shown that pharmacist interventions can effectively
identify, prevent, and solve pharmacotherapeutic prob-
lems [24,25]. Problems relating to safety were the most
frequently encountered in our study. Other researchers
have also identified a high frequency of issues related to
inappropriate dosage and safety [5,26-29]. Carcelero
et al. demonstrated that the most frequent issues with
hospitalized HIV-infected patients are caused by combi-
nations of contraindicated or not recommended drugs
and by dosage errors, which happen in approximately
one in five patients [5].
During one year of study, compared to the control
group, the intervention group showed higher percentage
of clinical outcomes, however there was no statistical dif-
ference. The better clinical response is associated with
slower disease progression and a lower risk of complica-
tions, opportunistic infections, and co-infections [1,30-32].
We speculate that owing to these better clinical outcomes,the intervention group needed less hospitalization, labora-
tory tests, and medical appointments than the control
group did.
Even though the difference in costs between the
groups was not statistically significant, we can expect
to see an overall, long-term cost analysis for the inter-
vention group due its better clinical outcomes than
the control group.
The lower costs associated with appointments and
hospitalizations generated by the intervention group,
compared with those of the control group, are consistent
with the literature. Horberg et al. [13] and McPherson-
Baker et al. [33] showed that the pharmacist’s presence
may decrease the number of appointments and, there-
fore, the costs for HIV-infected patients. A systematic
review that included 32 articles pertaining to the impact
of pharmaceutical care on HIV-infected patients showed
that pharmaceutical care is associated with cost savings
because it decreases the number of physician appoint-
ments, hospitalizations, and emergency visits [9]. A study
in China found that total hospitalization costs in a group
undergoing pharmaceutical care were significantly lower
than those in a control group ($1,442.3 [684.9] vs.
$1,729.6 [773.7], P <0.001) [34]. Furthermore, a Taiwanese
study showed that the replacement of intravenous levo-
floxacin with its oral form, performed by a pharmacist, de-
creased hospital stays from 27.2 to 16.1 days (P =0.001),
thereby lowering hospital costs [35]. Nevertheless, we
found no studies in the literature that described the im-
pact that pharmaceutical care has on the costs associated
with laboratory tests and procedures.
In this study, an economic analysis that correlates the ef-
fectiveness and the costs of pharmacotherapy demonstrated
that pharmaceutical care is dominant (less expensive
and more effective), when we consider the effective-
ness outcomes and the costs associated with appoint-
ments, laboratory tests, and hospitalizations. However,
the intervention group generated higher costs associ-
ated with procedures and total costs than those of the
control group. Furthermore, this study demonstrates
Figure 2 Optimal response immune for control and intervention groups. Abbreviation: CD4, CD4+ lymphocites; VL, viral load; w/o, without;
w/, with.
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Table 3 Study length of time and total daily costs (US$) for control and intervention groups
Control Group Intervention Group
N=51 N=51
Study period 6 m (i) 6 m (f) Final 6 m (i) 6 m (f) Final
Length of time (mean [SD], days) 180.2[41.8] 190.5[6.4] 370.7[41.3] 196.8[29.3] 190.2[56.4] 387.0[39.8]a
Appointments
Total cost (US$) /day 8.65 6.49 7.53 8.01 6.12 7.08
Individual mean [SD] (US$) 0.17[0.08] 0.13[0.09] 0.15[0.07] 0.16[0.09] 0.12[0.08] 0.14[0.07]
Laboratory tests
Total cost (US$) /day 38.07 25.35 31.48 33.33 22.96 28.24
Individual mean [SD] (US$) 0.75[0.74] 0.50[0.46] 0.62[0.43] 0.65[0.61] 0.45[0.43] 0.55[0.44]
Procedures
Total cost (US$) /day 3.75 4.81 4.29 20.28 2.11 11.36
Individual mean [SD] (US$) 0.07[0.22] 0.09[0.21] 0.08[0.17] 0.40[1.11] 0.04[0.09] 0.22[0.57]
Hospitalization
Total cost (US$) /day 2.62 2.53 2.57 2.30 1.17 1.74
Individual mean [SD] (US$) 0.05[0.30] 0.05[0.18] 0.05[0.17] 0.05[0.13] 0.02[0.10] 0.03[0.09]
Pharmacist
Total cost (US$) /day 0.0 0.0 0.0 2.20 1.39 1.80
Individual mean [SD] (US$) NA NA NA 0.05[0.02] 0.03[0.02] 0.04[0.02]
Total
Final cost/day (US$) 53.09 39.18 45.88 66.13 33.74 50.23
Individual mean [SD] (US$) 1.04[0.99] 0.77[0.70] 0.90[0.60] 1.30[1.33] 0.66[0.55] 1.00[0.81]
Total excluding procedures
Final cost/day (US$) 49.34 34.36 41.58 45.84 31.63 38.87
Individual mean [SD] (US$) 0.97[0.94] 0.67[0.63] 0.82[0.56] 0.90[0.71] 0.62[0.05] 0.77[0.53]
Note: a ANOVA results for repeated measures with a transformation by positions (P=0.057).
Abbreviations: 6m (i), initial 6 months; 6m (f), final 6 months; SD, Standard deviation.
Obs. The cost is the sum of the daily costs for all patients.
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with procedures. Here, if costs of procedures were dis-
regarded when calculating the daily costs, the total
costs of the intervention group would have been lower
than those of the control group.Table 4 Incremental Cost Effectiveness Ratio analysis per






Procedures Total Cost (with
procedures)
Viral load <50 copies/ml 2.36 1.45
Absence of co-infection 1.77 1.09
CD4+>200 cells/mm3 3.53 2.18
CD4+>350 cells/mm3 7.07 4.35




Abbreviation: ICER, Incremental Cost Effectiveness Ratio.Cost analysis identified a negative relationship when
considering total cost, which contradicts the literature.
According to Brennan et al., a $1.00 investment in
pharmaceutical care showed a $3.00 return [36]. A
meta-analysis demonstrated that 85% of the studies
describe positive economic impacts of pharmaceutical
care and concluded that the median benefit:cost ratio
was 4.68:1 [10]. However, it should be noted that costs
associated with laboratory tests and procedures were
not included in these studies. In our study, by disre-
garding the procedures cost, the relationship be-
comes positive (2.51:1). Inclusion of costs associated
with laboratory tests and procedures explains why
this study showed different results than the results
from the literature, and these differences clarify the
need for well-designed studies that include the costs
associated with procedures and laboratory tests, for
a better understanding of the relationships among
pharmaceutical care, HIV-infected patients, and the
economy.
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This study has some limitations. There was no
randomization of patients; the pharmacy staff was not
blinded; pharmacotherapy problems were not verified
for the control group (it was considered unethical to
identify pharmacotherapy problems without providing
any intervention); and the biggest limitation was our
inability to retrieve the costs associated with the use
of drugs, due to lack of information in the patient’s med-
ical charts. Several studies have analyzed the costs associ-
ated with the use of drugs [9,11-13,37] because they make
a significant contribution to health care costs, especially in
the context of hospital care, which represents 15%–25% of
total health care costs. In a study conducted at the Maine
Medical Center to guide the use of antibiotics, the
pharmacist performed 74 interventions, which reduced
the costs associated with antibiotics use, especially by re-
placing parenteral with oral formulations, generating sav-
ings of approximately $400.00 per patient and decreasing
the length of hospital stay [38]. Therefore, with more
comprehensive patient data, important additional savings
regarding the use of drugs to treat co-infections could
have been verified, since the intervention group had fewer
co-infections than the control group did. For example,
tuberculosis is common co-infection among HIV-infected
patients and its treatment consists of a combination of ri-
fampicin, isoniazid, and pyrazinamide [32], generating a
cost of $316.56 per patient [39].
Conclusion
Our study presents important information about the im-
pact that pharmaceutical care of HIV-infected patients
can have on costs associated with procedure and labora-
tory tests. This information could not be found else-
where in the literature, which indicates the need for
well-designed and more complete studies.
This work demonstrated that pharmaceutical care of
HIV-infected patients, for a one-year period, was able to
decrease the number of pharmacotherapy problems. In
addition, the intervention group presented higher percent-
age of better clinical outcomes and lower costs associated
with appointments, laboratory tests, and hospitalizations
than control group, however, there was no statistical dif-
ference; and, conversely, higher total costs and costs asso-
ciated with procedures than those of the control group
(no statistical significance). Additional pharmacoeconomic
studies focused on pharmaceutical care are necessary to
achieve a more comprehensive and reliable analysis.
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